C G Thanos1, R B Elliott. 1. Brown University, Department of Molecular Pharmacology, Physiology and Biotechnology, Providence, RI 02912, USA. cgthanos@gmail.com
Abstract
BACKGROUND: Allogeneic tissue-based therapies for Type I diabetes have demonstrated efficacy but are limited due to tissue-sourcing constraints, as the number of patients exceeds that of tissue donors. Porcine islets derived from designated pathogen-free sources could be an alternative, particularly if delivered in a way that evades the host immune system's rejection. METHODS: This review focuses on approaches designed to protect xenogeneic islets from immune rejection by provision of perm-selective barriers. RESULTS: Designated pathogen-free herds could provide a supply of wild-type porcine islets that are well tolerated when administered in a suitable protective delivery vehicle. Such barrier systems have enabled amelioration of diabetes in a variety of animal models and preliminary evidence suggests that similar results could be attained in humans. CONCLUSION: With advances in biomaterial design, source tissue selection, and the evolution of critical cell processing techniques, contemporary encapsulated porcine islet therapies offer a new level of clinical promise.
BACKGROUND: Allogeneic tissue-based therapies for Type I diabetes have demonstrated efficacy but are limited due to tissue-sourcing constraints, as the number of patients exceeds that of tissue donors. Porcine islets derived from designated pathogen-free sources could be an alternative, particularly if delivered in a way that evades the host immune system's rejection. METHODS: This review focuses on approaches designed to protect xenogeneic islets from immune rejection by provision of perm-selective barriers. RESULTS: Designated pathogen-free herds could provide a supply of wild-type porcine islets that are well tolerated when administered in a suitable protective delivery vehicle. Such barrier systems have enabled amelioration of diabetes in a variety of animal models and preliminary evidence suggests that similar results could be attained in humans. CONCLUSION: With advances in biomaterial design, source tissue selection, and the evolution of critical cell processing techniques, contemporary encapsulated porcine islet therapies offer a new level of clinical promise.
Authors: D Freimark; P Pino-Grace; S Pohl; C Weber; C Wallrapp; P Geigle; R Pörtner; P Czermak Journal: Transfus Med Hemother Date: 2010-03-08 Impact factor: 3.747
Authors: David K C Cooper; Shinichi Matsumoto; Adrian Abalovich; Takeshi Itoh; Nizar I Mourad; Pierre R Gianello; Eckhard Wolf; Emanuele Cozzi Journal: Transplantation Date: 2016-11 Impact factor: 4.939